← All indications
Leukemia, Large Granular Lymphocytic
A spectrum of disorders characterized by clonal expansions of the peripheral blood LYMPHOCYTE populations known as large granular lymphocytes which contain abundant cytoplasm and azurophilic granules. Subtypes develop from either CD3-negative NATURAL KILLER CELLS or CD3-positive T-CELLS. The clinical course of both subtypes can vary from spontaneous regression to progressive, malignant disease.
Drugs by status
Phase 3 trials (3)
Phase 2 trials (30)
- azacitidine
- methylprednisolone
- bnz132-1-40
- brentuximab vedotin
- busulfan
- lenalidomide
- tacrolimus
- naltrexone
- msk-2206
- zarnestra
- ipilimumab
- sunitinib
- allogeneic hematopoietic stem cells
- ruxolitinib
- cyclosporine
- mycophenolate
- cyclophosphamide
- allogeneic lymphocytes
- alemtuzumab
- Anti-thymocyte Globulin (Rabbit)
- anti-cd7 car-pnk cells
- autologous umbilical cord blood
- fludarabine
- rituximab
- thiotepa
- melphalan
- autologous hematopoietic stem cells
- abc008
- ppmx-t003
- dr-01
Phase 1 trials (21)
Organizations
Organization Involved with Phase 3 Indications (9)
Organization Involved with Phase 2 Indications (20)
- Seattle Genetics
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
- Bioniz Therapeutics
- National Institutes of Health (NIH)
- National Cancer Institute (NCI)
- National Heart, Lung, and Blood Institute (NHLBI)
- Case Western Reserve University
- German CLL Study Group
- University of Washington
- Northwestern University
- Rutgers University
- Stanford University
- Thomas Jefferson University
- University of Medicine and Dentistry of New Jersey
- University of Chicago
- University of Texas at Houston
- State University of New York, Buffalo
- Universitaetsklinikum Schleswig-Holstein
- University of Rennes
- Hefei University